Daehwa Pharmaceutical signs Chinese technology transfer agreement of ‘Liporaxel Soln’ for USD 25 million
Daehwa Pharmaceutical announced on the 6th that the company signed a technology transfer agreement of the world’s first approved oral paclitaxel anticancer drug(Korean product name: Liporaxel Soln) for USD 25 million and other royalties with Chinese RMX Biopharma.
The total technology licensing ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.